Sigyn Therapeutics, Inc. (SIGY)
- Previous Close
5.75 - Open
6.25 - Bid --
- Ask --
- Day's Range
6.25 - 6.34 - 52 Week Range
0.15 - 12.80 - Volume
200 - Avg. Volume
109 - Market Cap (intraday)
7.762M - Beta (5Y Monthly) -1.03
- PE Ratio (TTM)
-- - EPS (TTM)
-3.77 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.
www.sigyntherapeutics.comRecent News: SIGY
Performance Overview: SIGY
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SIGY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SIGY
Valuation Measures
Market Cap
7.76M
Enterprise Value
10.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.85
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-468.80%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.15M
Diluted EPS (ttm)
-3.77
Balance Sheet and Cash Flow
Total Cash (mrq)
11.69k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
307.1k
Company Insights: SIGY
SIGY does not have Company Insights